A Novel Scoring System Based on Peripheral Blood Test in Predicting Grade and Prognosis of Patients with Glioma

References

• Ostrom QT, Gittleman H, Stetson L, et al. Epidemiology of gliomas. Cancer Treat Res. 2015;163(3):1–14.25468222
   PubMedGoogle Scholar
• Anton K, Baehring JM, Mayer T. Glioblastoma multiforme: overview of current treatment and future perspectives. Hematol Oncol Clin North Am. 2012;26(4):825–853. doi:10.1016/j.hoc.2012.04.00622794286
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820. doi:10.1007/s00401-016-1545-127157931
   PubMed Web of Science ®Google Scholar
• Nabors LB, Portnow J, Ammirati M, et al. NCCN guidelines insights: central nervous system cancers, Version 1.2017. J Natl Compr Canc Netw. 2017;15(11):1331–1345. doi:10.6004/jnccn.2017.016629118226
   PubMed Web of Science ®Google Scholar
• Brito C, Azevedo A, Esteves S, et al. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. BMC Cancer. 2019;19(1):968. doi:10.1186/s12885-019-6177-031623593
   PubMed Web of Science ®Google Scholar
• Labussiere M, Boisselier B, Mokhtari K, et al. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology. 2014;83(13):1200–1206. doi:10.1212/WNL.000000000000081425150284
   PubMed Web of Science ®Google Scholar
• Leu S, von Felten S, Frank S, et al. IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. Neuro-Oncology. 2013;15(4):469–479. doi:10.1093/neuonc/nos31723408861
   PubMed Web of Science ®Google Scholar
• Molenaar RJ, Verbaan D, Lamba S, et al. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro-Oncology. 2014;16(9):1263–1273. doi:10.1093/neuonc/nou00524510240
   PubMed Web of Science ®Google Scholar
• Li J, Niu X, Gan Y, et al. Clinical and pathologic features and prognostic factors for recurrent gliomas. World Neurosurg. 2019;128:e21–e30. doi:10.1016/j.wneu.2019.02.21030880199
   PubMed Web of Science ®Google Scholar
• Louveau A, Harris TH, Kipnis J. Revisiting the mechanisms of CNS immune privilege. Trends Immunol. 2015;36(10):569–577. doi:10.1016/j.it.2015.08.00626431936
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.01321376230
   PubMed Web of Science ®Google Scholar
• Colotta F, Allavena P, Sica A, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073–1081. doi:10.1093/carcin/bgp12719468060
   PubMed Web of Science ®Google Scholar
• Michelson N, Rincon-Torroella J, Quiñones-Hinojosa A, et al. Exploring the role of inflammation in the malignant transformation of low-grade gliomas. J Neuroimmunol. 2016;297:132–140. doi:10.1016/j.jneuroim.2016.05.01927397086
   PubMed Web of Science ®Google Scholar
• Massara M, Persico P, Bonavita O, et al. Neutrophils in Gliomas. Front Immunol. 2017;8:1349. doi:10.3389/fimmu.2017.0134929123517
   PubMed Web of Science ®Google Scholar
• Zhou W, Ke SQ, Huang Z, et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol. 2015;17(2):170–182. doi:10.1038/ncb309025580734
   PubMed Web of Science ®Google Scholar
• Komohara Y, Ohnishi K, Kuratsu J, et al. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol. 2008;216(1):15–24. doi:10.1002/path.v216:118553315
   PubMed Web of Science ®Google Scholar
• Templeton AJ, McNamara MG, Seruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124. doi:10.1093/jnci/dju12424875653
   PubMedGoogle Scholar
• Rondon AMR, Kroone C, Kapteijn MY, et al. Role of tissue factor in tumor progression and cancer-associated thrombosis. Semin Thromb Hemost. 2019;45(4):396–412. doi:10.1055/s-0039-168789531096312
   PubMed Web of Science ®Google Scholar
• Perisanidis C, Psyrri A, Cohen EE, et al. Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors: a systematic review and meta-analysis. Cancer Treat Rev. 2015;41(10):960–970. doi:10.1016/j.ctrv.2015.10.00226604093
   PubMed Web of Science ®Google Scholar
• He ZQ, Duan H, Ke C, et al. Evaluation of cumulative prognostic score based on pretreatment plasma fibrinogen and serum albumin levels in patients with newly diagnosed high-grade gliomas. Oncotarget. 2017;8(30):49605–49614. doi:10.18632/oncotarget.1784928548947
   PubMedGoogle Scholar
• He J, Pan H, Liang W, et al. Prognostic effect of albumin-to-globulin ratio in patients with solid tumors: a systematic review and meta-analysis. J Cancer. 2017;8(19):4002–4010. doi:10.7150/jca.2114129187875
   PubMed Web of Science ®Google Scholar
• Palumbo JS, Talmage KE, Massari JV, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005;105(1):178–185. doi:10.1182/blood-2004-06-227215367435
   PubMed Web of Science ®Google Scholar
• Simpson-Haidaris PJ, Rybarczyk B. Tumors and fibrinogen. The Role of Fibrinogen as an Extracellular Matrix Protein. Ann N Y Acad Sci. 2001;936(1):406–425.11460495
   PubMedGoogle Scholar
• Liu X, Liu Z, Lin E, et al. A cumulative score based on preoperative fibrinogen and the neutrophil-lymphocyte ratio to predict outcomes in resectable gastric cancer. Cancer Manag Res. 2018;10:3007–3014. doi:10.2147/CMAR.S17465630214295
   PubMed Web of Science ®Google Scholar
• Nieswandt B, Hafner M, Echtenacher B, et al. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 1999;59(6):1295–1300.10096562
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Yamamoto Y, Yokota S, et al. Involvement of interleukin-6 in the elevation of plasma fibrinogen levels in lung cancer patients. Jpn J Clin Oncol. 1998;28(12):740–744. doi:10.1093/jjco/28.12.7409879291
   PubMed Web of Science ®Google Scholar
• Sahni A, Francis CW. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood. 2000;96(12):3772–3778. doi:10.1182/blood.V96.12.377211090059
   PubMed Web of Science ®Google Scholar
• Sahni A, Simpson-Haidaris PJ, Sahni SK, et al. Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor-2 (FGF-2). J Thromb Haemost. 2008;6(1):176–183. doi:10.1111/j.1538-7836.2007.02808.x17949478
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi:10.1038/nature0720518650914
   PubMed Web of Science ®Google Scholar
• Zheng SH, Huang JL, Chen M, et al. Diagnostic value of preoperative inflammatory markers in patients with glioma: a multicenter cohort study. J Neurosurg. 2018;129(3):583–592. doi:10.3171/2017.3.JNS16164829099300
   PubMed Web of Science ®Google Scholar
• Lei YY, Li YT, Hu QL, et al. Prognostic impact of neutrophil-to-lymphocyte ratio in gliomas: a systematic review and meta-analysis. World J Surg Oncol. 2019;17(1):152. doi:10.1186/s12957-019-1686-531472673
   PubMed Web of Science ®Google Scholar
• Lorente D, Mateo J, Templeton AJ, et al. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol. 2015;26(4):750–755. doi:10.1093/annonc/mdu58725538172
   PubMed Web of Science ®Google Scholar
• Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410(6832):1107–1111. doi:10.1038/3507412211323675
   PubMed Web of Science ®Google Scholar
• Jablonska J, Leschner S, Westphal K, et al. Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest. 2010;120(4):1151–1164. doi:10.1172/JCI3722320237412
   PubMed Web of Science ®Google Scholar
• Liu J, Dai Y, Zhou F, et al. The prognostic role of preoperative serum albumin/globulin ratio in patients with bladder urothelial carcinoma undergoing radical cystectomy. Urol Oncol. 2016;34(11):484.e1–484.e8. doi:10.1016/j.urolonc.2016.05.024
   Web of Science ®Google Scholar
• Ataseven B, Du Bois A, Reinthaller A, et al. Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery. Gynecol Oncol. 2015;138(3):560–565.26163893
   PubMed Web of Science ®Google Scholar
• Chiang JM, Chang CJ, Jiang SF, et al. Pre-operative serum albumin level substantially predicts post-operative morbidity and mortality among patients with colorectal cancer who undergo elective colectomy. Eur J Cancer Care (Engl). 2017;26:2. doi:10.1111/ecc.12403
   Web of Science ®Google Scholar
• Kanda M, Mizuno A, Tanaka C, et al. Nutritional predictors for postoperative short-term and long-term outcomes of patients with gastric cancer. Medicine. 2016;95(24):e3781. doi:10.1097/MD.000000000000378127310954
   PubMed Web of Science ®Google Scholar
• Azab B, Kedia S, Shah N, et al. The value of the pretreatment albumin/globulin ratio in predicting the long-term survival in colorectal cancer. Int J Colorectal Dis. 2013;28(12):1629–1636. doi:10.1007/s00384-013-1748-z23857599
   PubMed Web of Science ®Google Scholar
• Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448–454. doi:10.1056/NEJM1999021134006079971870
   PubMed Web of Science ®Google Scholar
• Li Q, Meng X, Liang L, et al. High preoperative serum globulin in rectal cancer treated with neoadjunctive chemoradiation therapy is a risk factor for poor outcome. Am J Cancer Res. 2015;5(9):2856–2864.26609491
   PubMed Web of Science ®Google Scholar
• Gast MC, Van Gils CH, Wessels LF, et al. Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS. Oncol Rep. 2009;22(1):205–213. doi:10.3892/or_0000042619513525
   PubMed Web of Science ®Google Scholar
• Xu WZ, Li F, Xu ZK, et al. Preoperative albumin-to-globulin ratio and prognostic nutrition index predict prognosis for glioblastoma. Onco Targets Ther. 2017;10:725–733. doi:10.2147/OTT.S12744128223828
   PubMed Web of Science ®Google Scholar
• Huang W, Wang S, Zhang H, et al. Prognostic significance of combined fibrinogen concentration and neutrophil-to-lymphocyte ratio in patients with resectable non-small cell lung cancer. Cancer Biol Med. 2018;15(1):88–96. doi:10.20892/j.issn.2095-3941.2017.012429545972
   PubMed Web of Science ®Google Scholar
• Kao HK, Lofstrand J, Loh CY, et al. Nomogram based on albumin and neutrophil-to-lymphocyte ratio for predicting the prognosis of patients with oral cavity squamous cell carcinoma. Sci Rep. 2018;8(1):13081. doi:10.1038/s41598-018-31498-z30166572
   PubMed Web of Science ®Google Scholar